Cited by 233RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryAdvancements in Transdermal Drug Delivery

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Long-term storage of lipid-like nanoparticles for mRNA delivery

Open access

Zhao, Pengxuan, Hou, Xucheng, Yan, Jingyue, Du, Shi, Xue, Yonger, Li, Wenqing, Xiang, Guangya, Dong, Yizhou·2020·Bioactive Materials

DOI 10.1016/j.bioactmat.2020.03.001PMC PMC7078456

Open this paper in CoChat — free account Open PDF

Abstract

Lipid-like nanoparticles (LLNs) have been extensively explored for messenger RNA (mRNA) delivery in various biomedical applications. However, the long-term storage of these nanoparticles is still a challenge for their clinical translation. In this study, we investigated a series of conditions for the long-term storage of LLNs with encapsulation of mRNA. We evaluated the stability of LLNs with different concentrations of cryoprotectants (sucrose, trehalose or mannitol) under the conditions of freezing or lyophilization processes. Through in vitro and in vivo mRNA delivery studies, we identified the optimal storage condition, and found that the addition with 5% (w/v) sucrose or trehalose to LLNs could remain their mRNA delivery efficiency for at least three months in the liquid nitrogen storage condition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.bioactmat.2020.03.001

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Graphical abstract CC BY-NC-ND · PubMed Central

Fig. 1 The long-term stability of LLNs stored at 4 °C in aqueous condition. (A) Size of LLNs at different time points. (B) Relative luminescence intensity of LLNs. All data are presented as mean ± s.d (n = 3). Statistical significance was analyzed by the two-tailed Student's t-test. **P < 0.01, ***P < 0.001. ns: not significant.CC BY-NC-ND · PubMed Central

Fig. 2 The stability of LLNs containing cryoprotectants with different concentrations (w/v) after three freeze–thaw cycles. (A) Size of LLNs. (B) Relative luminescence intensity of LLNs. All data are presented as mean ± s.d (n = 3). Statistical significance was analyzed by the two-tailed Student's t-test. **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central

Fig. 3 The stability of LLNs containing cryoprotectants with different concentrations (w/v) stored in liquid nitrogen. (A) Size of LLNs. (B) Relative luminescence intensity of LLNs. All data are presented as mean ± s.d (n = 3). Statistical significance was analyzed by the two-tailed Student's t-test. **P < 0.01.CC BY-NC-ND · PubMed Central

Fig. 4 The stability of lyophilized LLNs (A) Size of LLNs. (B) Relative luminescence intensity of LLNs. All data are presented as mean ± s.d (n = 3). Statistical significance was analyzed by the two-tailed Student's t-test. **P < 0.01, ***P < 0.001.CC BY-NC-ND · PubMed Central

Fig. 5 In vivo mRNA delivery efficiency. Total bioluminescence signal (A, C) and normalized bioluminescence signal with tissue weight (B, D) of different LLNs. (A, B) were LLNs stored for 1 week, (C, D) were LLNs stored for 3 months. All data are presented as mean ± s.d (n = 3). Statistical significance was analyzed by the two-tailed Student's t-test. ***P < 0.001.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · cited 1×
“LLNs-mediated mRNA delivery in vivo involves complex interactions with serum proteins [34].”
Background
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
An overview of liposome lyophilization and its future potential
Chen, C., Han, D., Cai, C., & Tang, X. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.024 · Cited by 547
Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA
Islam, M. A., Xu, Y., Tao, W., Ubellacker, J. M., Lim, M., Aum, D., Lee, G. Y., Zhou, K., Zope, H., Yu, M., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0284-0 · Cited by 339
Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization
Ball, R., Bajaj, P., & Whitehead, K. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s123062 · Cited by 333
High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811276115 · Cited by 313
In Vitro and in Vivo mRNA Delivery Using Lipid-Enveloped pH-Responsive Polymer Nanoparticles
Su, X., Fricke, J., Kavanagh, D. G., & Irvine, D. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100390w · Cited by 287
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Self-citation
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E., & Sahay, G. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.015 · Cited by 260

Show all 34 references

Sorted by citations

Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Self-citation
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Chemistry of Lipid Nanoparticles for RNA Delivery
Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00544 · Cited by 917
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development
Mehta, M., Bui, T. A., Yang, X., Aksoy, Y. A., Goldys, E. M., & Deng, W. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00032 · Cited by 776
Nanomaterial Delivery Systems for mRNA Vaccines
Buschmann, M. D., Carrasco, M. J., Alishetty, S., Paige, M., Alameh, M. G., & Weissman, D. (2021) · Vaccines · doi:10.3390/vaccines9010065 · Cited by 582
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517
Self-assembled mRNA vaccines
Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514
A Comprehensive Review of mRNA Vaccines
Gote, V., Bolla, P. K., Kommineni, N., Butreddy, A., Nukala, P. K., Palakurthi, S. S., & Khan, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032700 · Cited by 457
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 348
Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine
Muramatsu, H., Lam, K., Bajusz, C., Laczkó, D., Karikó, K., Schreiner, P., Martin, A., Lutwyche, P., Heyes, J., & Pardi, N. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.001 · Cited by 331
Principles for designing an optimal mRNA lipid nanoparticle vaccine
Kon, E., Elia, U., & Peer, D. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.09.016 · Cited by 269
Lipid Nanoparticle–mRNA Formulations for Therapeutic Applications
Wang, C., Zhang, Y., & Dong, Y. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00550 · Cited by 276
Self-citation
Freeze-drying of nanoparticles: How to overcome colloidal instability by formulation and process optimization
Trenkenschuh, E., & Frieß, W. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.05.024 · Cited by 246
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Blenke, E. O., Örnskov, E., Schöneich, C., Nilsson, G. Å., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.001 · Cited by 221
Lipid nanoparticles for siRNA delivery in cancer treatment
Moukhtari, S. H. E., Garbayo, E., Amundarain, A., Pascual‐Gil, S., Carrasco‐Leon, A., Prósper, F., Agirre, X., & Blanco‐Prieto, M. J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.054 · Cited by 221
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Parra Sperberg, R. A., Huang, P.-S., Participants, E., & Das, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab764 · Cited by 197
A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines
Straeten, A. V., Sarmadi, M., Daristotle, J. L., Kanelli, M., Tostanoski, L. H., Collins, J., Pardeshi, A., Han, J., Varshney, D., Eshaghi, B., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01774-z · Cited by 199
Combinatorial development of nebulized mRNA delivery formulations for the lungs
Jiang, A. Y., Witten, J. J., Raji, I. O., Eweje, F., MacIsaac, C., Meng, S., Oladimeji, F. A., Hu, Y., Manan, R. S., Langer, R., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01548-3 · Cited by 205
Recent Advances in Lipid Nanoparticles for Delivery of mRNA
Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F. H., Zhang, Z., Li, Y., & Huang, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122682 · Cited by 190
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172
Self-citation
Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures
Meulewaeter, S., Nuytten, G., Cheng, M. H. Y., Smedt, S. C. D., Cullis, P. R., Beer, T. D., Lentacker, I., & Verbeke, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.039 · Cited by 154
Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines
Kim, B., Hosn, R. R., Remba, T. K., Yun, D. S., Li, N., Abraham, W. D., Melo, M. B., Cortés, M., Li, B., Zhang, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.022 · Cited by 157
Self-citation
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Ai, L., Li, Y., Zhou, L., Yao, W., Zhang, H., Hu, Z., Han, J., Wang, W., Wu, J., Xu, P., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00517-9 · Cited by 148
mRNA in the Context of Protein Replacement Therapy
Vavilis, T., Stamoula, Ε., Ainatzoglou, A., Sachinidis, A., Lamprinou, M., Dardalas, I., & Vizirianakis, I. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010166 · Cited by 145
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
Mendonça, M. C. P., Kont, A., Kowalski, P. S., & O’Driscoll, C. M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103505 · Cited by 143
A Bio‐Inspired Multifunctional Hydrogel Network with Toughly Interfacial Chemistry for Dendrite‐Free Flexible Zinc Ion Battery
Yang, S., Wu, Q., Li, Y., Luo, F., Zhang, J., Chen, K., You, Y., Huang, J., Xie, H., & Chen, Y. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202409160 · Cited by 126
Engineering therapeutical extracellular vesicles for clinical translation
Ma, Y., Dong, S., Grippin, A., Teng, L., Lee, A. S., Kim, B. Y. S., & Jiang, W. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.08.007 · Cited by 136
From structural design to delivery: mRNA therapeutics for cancer immunotherapy
Zhou, F., Huang, L., Li, S., Yang, W., Chen, F., Cai, Z., Liu, X., Xu, W., Lehto, V., Lächelt, U., et al. (2023) · Exploration · doi:10.1002/exp.20210146 · Cited by 117
Advances in mRNA non-viral delivery approaches
Ibba, M. L., Ciccone, G., Esposito, C. L., Catuogno, S., & Giangrande, P. H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113930 · Cited by 107
Current Developments and Challenges of mRNA Vaccines
Chen, J., Chen, J., & Xu, Q. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110220-031722 · Cited by 111
Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs
Li, Y., Ye, Z., Yang, H., & Xu, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.04.013 · Cited by 102
Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach
Haghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 121
The Effect of Cryoprotectants and Storage Conditions on the Transfection Efficiency, Stability, and Safety of Lipid‐Based Nanoparticles for mRNA and DNA Delivery
Kafetzis, K. N., Papalamprou, N., McNulty, E., Thong, K. X., Sato, Y., Mironov, A., Purohit, A., Welsby, P. J., Harashima, H., Yu‐Wai‐Man, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203022 · Cited by 98
Engineering nanoparticle toolkits for mRNA delivery
Sun, B., Wu, W., Narasipura, E. A., Ma, Y., Yu, C., Fenton, O. S., & Song, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115042 · Cited by 95
Stabilizing vaccines via drying: Quality by design considerations
Ghaemmaghamian, Z., Zarghami, R., Walker, G., O’Reilly, E. J., & Ziaee, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114313 · Cited by 90
A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery
Gerhardt, A., Voigt, E. A., Archer, M. C., Reed, S., Larson, E., Hoeven, N. V., Kramer, R. M., Fox, C. B., & Casper, C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.009 · Cited by 86
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89
In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy
Escalona-Rayo, O., Zeng, Y., Knol, R. A., Kock, T. J. F., Aschmann, D., Slütter, B., & Kros, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115065 · Cited by 89
Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications
Lopes, C., Cristóvão, J. S., Silvério, V., Lino, P. R., & Fonte, P. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2135502 · Cited by 88
The mixing method used to formulate lipid nanoparticles affects mRNA delivery efficacy and organ tropism
Petersen, D. M. S., Chaudhary, N., Arral, M. L., Weiss, R. M., & Whitehead, K. A. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.10.006 · Cited by 86
mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
Chavda, V. P., Soni, S., Vora, L. K., Soni, S., Khadela, A. D., & Ajabiya, J. (2022) · Vaccines · doi:10.3390/vaccines10122150 · Cited by 89
Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses
Wan, J., Wang, Z., Wang, L., Wu, L., Zhang, C., Zhou, M., Fu, Z. F., & Zhao, L. (2023) · mBio · doi:10.1128/mbio.01775-23 · Cited by 90
A comprehensive comparison of DNA and RNA vaccines
Wang, C., & Yuan, F. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115340 · Cited by 90
Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates
Suzuki, Y., Miyazaki, T., Muto, H., Kubara, K., Mukai, Y., Watari, R., Sato, S., Kondo, K., Tsukumo, S., Yasutomo, K., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.09.017 · Cited by 83
Plant-Derived Extracellular Vesicles: A New Revolutionization of Modern Healthy Diets and Biomedical Applications
Lo, K.-J., Wang, M., Ho, C., & Pan, M. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c06867 · Cited by 84
Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine
Li, M., Jia, L., Xie, Y., Ma, W., Yan, Z., Liu, F., Deng, J., Zhu, A., Siwei, X., Su, W., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00732-9 · Cited by 81
Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle
Yang, T., Li, C., Wang, X., Zhao, D., Zhang, M., Cao, H., Liang, Z., Xiao, H., Liang, X., Weng, Y., et al. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.07.003 · Cited by 78
Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids
Lamoot, A., Lammens, J., Lombaerde, E. D., Zhong, Z., Gontsarik, M., Chen, Y., Beer, T. R. M. D., & Geest, B. G. D. (2023) · Biomaterials Science · doi:10.1039/d2bm02031a · Cited by 78
Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines
Li, Z., Zhang, X., Ho, W., Li, F., Gao, M., Bai, X., & Xu, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c07822 · Cited by 79
Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA
Friis, K. P., Gracin, S., Oag, S., Leijon, A., Sand, E., Lindberg, B., Lázaro‐Ibáñez, E., Lindqvist, J., Whitehead, K. A., & Bak, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.031 · Cited by 79
Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals
Emami, F., Shokooh, M. K., & Yazdi, S. J. M. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00610-x · Cited by 74
Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings
Fan, Y., Rigas, D., Kim, L. J., Chang, F.-P., Zang, N., McKee, K., Kemball, C. C., Yu, Z., Winkler, P., Su, W.-C., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.052 · Cited by 75
mRNA vaccines: Past, present, future
Karam, M., & Daoud, G. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.05.003 · Cited by 74
Nanotechnology‐Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID‐19 Vaccines
Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., Presutti, D., Wang, Q., Costantini, M., Sio, L. D., et al. (2021) · Small Methods · doi:10.1002/smtd.202100402 · Cited by 77
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 75
Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles
Henderson, M. I., Eygeris, Y., Jozić, A., Herrera‐Barrera, M., & Sahay, G. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00587 · Cited by 71
Ionizable Lipid Nanoparticles for mRNA Delivery
Tang, X., Zhang, Y., & Han, X. (2023) · Advanced NanoBiomed Research · doi:10.1002/anbr.202300006 · Cited by 76
Comprehensive Optimization of a Freeze-Drying Process Achieving Enhanced Long-Term Stability and In Vivo Performance of Lyophilized mRNA-LNPs
Alejo, T., Toro-Córdova, A., Fernández, L., Rivero, A., Stoian, A. M., Pérez, L., Navarro, V., Martínez-Oliván, J., & de Miguel, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910603 · Cited by 76
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 64
Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Youssef, M., Hitti, C., Fulber, J. P. C., & Kamen, A. (2023) · Biomolecules · doi:10.3390/biom13101497 · Cited by 63
Lipid‐Polymer Hybrid “Particle‐in‐Particle” Nanostructure Gene Delivery Platform Explored for Lyophilizable DNA and mRNA COVID‐19 Vaccines
Li, Z., Zhang, X., Ho, W., Bai, X., Jaijyan, D. K., Li, F., Kumar, R., Kolloli, A., Subbian, S., Zhu, H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204462 · Cited by 62
Nanomaterials‐Mediated Co‐Stimulation of Toll‐Like Receptors and CD40 for Antitumor Immunity
Yan, J., Zhang, Y., Du, S., Hou, X., Li, W., Zeng, C., Zhang, C., Cheng, J. K. J., Deng, B., McComb, D. W., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207486 · Cited by 61
Self-citation
Freeze-drying for the preservation of immunoengineering products
Kommineni, N., Butreddy, A., Jyothi, V. G. S. S., & Angsantikul, P. (2022) · iScience · doi:10.1016/j.isci.2022.105127 · Cited by 63
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
Clinical progress of nanomedicine-based RNA therapies
Lim, S. A., Cox, A., Tung, M., & Chung, E. J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.018 · Cited by 56
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 60
mRNA vaccines contribute to innate and adaptive immunity to enhance immune response in vivo
Cao, Q., Fang, H., & Tian, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122628 · Cited by 56
Advances in Nanomaterial-Based Platforms to Combat COVID-19: Diagnostics, Preventions, Therapeutics, and Vaccine Developments
Mahmud, N., Anik, M. I., Hossain, M. K., Khan, M. I., Uddin, S., Ashrafuzzaman, M., & Rahaman, M. M. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00123 · Cited by 53
An Overview of the Stability and Delivery Challenges of Commercial Nucleic Acid Therapeutics
Ingle, R. G., & Fang, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041158 · Cited by 56
Transdermal delivery for gene therapy
Singh, P., Muhammad, I., Nelson, N. E., Tran, K. T. M., Vinikoor, T., Chorsi, M. T., D’Orio, E., & Nguyen, T. D. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01138-1 · Cited by 52
Lipid Nanoparticle and Liposome Reference Materials: Assessment of Size Homogeneity and Long-Term −70 °C and 4 °C Storage Stability
Jakubek, Z. J., Chen, S., Zaifman, J., Tam, Y. Y. C., & Zou, S. (2023) · Langmuir · doi:10.1021/acs.langmuir.2c02657 · Cited by 55
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 53
Analytical techniques for the characterization of nanoparticles for mRNA delivery
Nogueira, S. S., Samaridou, E., Simon, J., Simon, F., Beck‐Broichsitter, M., & Mehta, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114235 · Cited by 57
Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 52
Advances in the design and delivery of RNA vaccines for infectious diseases
Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 52
Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size
Shi, R., Liu, X., Wang, Y., Pan, M., Wang, S., Shi, L., & Ni, B. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2342592 · Cited by 48
Lipid nanomaterials-based RNA therapy and cancer treatment
Zhang, X., Hai, L., Gao, Y., Yu, G., & Sun, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.004 · Cited by 46
Development of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects
Kafle, U., Truong, H. Q., Cao, T. G. N., & Meng, F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00826 · Cited by 47
Design and lyophilization of mRNA-encapsulating lipid nanoparticles
Wang, T., Yu, T., Li, W., Liu, Q., Sung, T., & Higuchi, A. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124514 · Cited by 42
Self-citation
Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines
Young, R. E., Hofbauer, S. I., & Riley, R. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.04.004 · Cited by 41
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
Wang, H., Wang, Z.-G., & Liu, S. (2022) · Molecules · doi:10.3390/molecules27175607 · Cited by 41
Protein-based delivery systems for RNA delivery
Zhu, H., Luo, H., Chang, R., Yang, Y., Liu, D., Ji, Y. R., Qin, H., Rong, H., & Yin, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.032 · Cited by 39
Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
Hermosilla, J., Alonso-García, A., Salmerón‐García, A., Barrera, J. C., Medina-Castillo, A. L., Pérez-Robles, R., & Navas, N. (2023) · Vaccines · doi:10.3390/vaccines11111635 · Cited by 40
Formulation screening of lyophilized mRNA-lipid nanoparticles
Ruppl, A., Kiesewetter, D. C., Köll-Weber, M., Lemazurier, T., Süss, R., & Allmendinger, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125272 · Cited by 39
Oral delivery of liquid mRNA therapeutics by an engineered capsule for treatment of preclinical intestinal disease
Huang, X., Chuang, L. I. U., Sharma, S. N., You, X., Chen, S., Li, Y., Liu, H.-J., Liu, B., Saiding, Q., Chen, W., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu1493 · Cited by 39
Development of a Lyophilized Off-the-Shelf Mesenchymal Stem Cell-Derived Acellular Therapeutic
Driscoll, J., Yan, I. K., & Patel, T. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040849 · Cited by 39
Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects
Xu, Y., Thakur, A., Zhang, Y., & Foged, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020177 · Cited by 38
Resveratrol-Loaded Polymeric Nanoparticles: The Effects of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) on Physicochemical and Biological Properties against Breast Cancer In Vitro and In Vivo
de Freitas, P. G. C., Arruda, B. R., Mendes, M. G. A., de Freitas, J. V. B., da Silva, M. E., Sampaio, T. L., Petrilli, R., & Eloy, J. O. (2023) · Cancers · doi:10.3390/cancers15102802 · Cited by 37
Why mRNA-ionizable LNPs formulations are so short-lived: causes and way-out
De, A., & Ko, Y. T. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2162876 · Cited by 37
Development of nucleic acid medicines based on chemical technology
Kawamoto, Y., Wu, Y., Takahashi, Y., & Takakura, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114872 · Cited by 34
Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and drying
AboulFotouh, K., Southard, B., Dao, H. M., Xu, H., Moon, C., Williams, R. O., & Cui, Z. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123688 · Cited by 34
Advances in nanomaterials for the diagnosis and treatment of head and neck cancers: A review
Yu, C., Li, L., Wang, S., Xu, Y., Wang, L., Huang, Y., Hieawy, A., Liu, H., & Ma, J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.08.010 · Cited by 34
Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery
Eygeris, Y., Henderson, M. I., Curtis, A. G., Jozić, A., Stoddard, J., Reynaga, R., Chirco, K. R., Su, G., Neuringer, M., Lauer, A. K., et al. (2024) · Small · doi:10.1002/smll.202400815 · Cited by 34
Opportunities and Challenges for mRNA Delivery Nanoplatforms
Zhang, Y., Hu, Y., Tian, H., & Chen, X. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c03898 · Cited by 33
mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles
McKenzie, R. E., Minnell, J. J., Ganley, M., Painter, G. F., & Draper, S. L. (2023) · Current Protocols · doi:10.1002/cpz1.898 · Cited by 38
Path towards mRNA delivery for cancer immunotherapy from bench to bedside
Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 33
Zwitterionic Polymer-Decorated Lipid Nanoparticles for mRNA Delivery in Mammalian Cells
Khunsuk, P.-O., Pongma, C., Palaga, T., & Hoven, V. P. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00649 · Cited by 30

Authors: Zhao, P., Hou, X., Yan, J., Du, S., Xue, Y., Li, W., Xiang, G., & Dong, Y.
Affiliations: Huazhong University of Science and Technology (CN)
The Ohio State University (US)
Corresponding author: Xiang, Guangya
Dong, Yizhou
ORCID: Hou, Xucheng
Xue, Yonger
Li, Wenqing
Xiang, Guangya
Dong, Yizhou
Venue: Bioactive Materials
Publisher: Elsevier BV
Published: 2020-06
Volume: 5
Issue: 2
Pages: 358-363
ISSN: 2097-1192 (ISSN-L)
2452-199X
DOI: 10.1016/j.bioactmat.2020.03.001
PMC: PMC7078456
OpenAlex: W3011313923
Cited by: 233
References: 34
Citations by year: 2026: 17 · 2025: 39 · 2024: 48 · 2023: 53 · 2022: 47 · 2021: 24 · 2020: 4
FWCI: 10.38
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Bioactive Materials (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Ohio State University
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords: mRNA delivery, long-term storage, cryoprotectants, sucrose, trehalose, mannitol, freeze-drying, freezing, liquid nitrogen storage, nanoparticle stability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-term storage of lipid-like nanoparticles for mRNA delivery

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks